<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282126</url>
  </required_header>
  <id_info>
    <org_study_id>N01 AR052275</org_study_id>
    <secondary_id>27653</secondary_id>
    <nct_id>NCT00282126</nct_id>
  </id_info>
  <brief_title>Potassium Citrate to Prevent Age Related Bone Loss</brief_title>
  <official_title>Potassium Citrate to Prevent Age Related Bone Loss: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis, a disease in which the bones become weak and are more likely to break, is a&#xD;
      major health problem in the United States. Too much acid in the body appears to be linked to&#xD;
      loss of calcium via urine, bone loss, and muscle breakdown. The purpose of this study is to&#xD;
      determine the effect of various doses of potassium citrate, a supplement that can neutralize&#xD;
      acid, on bone density and muscle mass in older, healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 10 million adults in the United States have osteoporosis, and another 18 million have&#xD;
      low bone mass, a risk factor for developing this disease. Each year, approximately 1.5&#xD;
      million fractures are associated with osteoporosis. Adequate intake of calcium and vitamin D&#xD;
      is the current nutritional approach to preventing age-related bone loss. However, even with&#xD;
      sufficient levels of these nutrients, bone loss can still occur. Too much acid in the body,&#xD;
      caused by diet, aging, and protein metabolism, appears to be linked to loss of calcium via&#xD;
      urine, bone loss, and muscle breakdown. Potassium citrate can neutralize acids. The purpose&#xD;
      of this study is to determine the effect of various doses of potassium citrate on bone&#xD;
      density and muscle mass in older, healthy adults.&#xD;
&#xD;
      This study will last 6 months. Baseline measurements will take place from Weeks 1 through 4.&#xD;
      During this time, participants will first receive a placebo over a 2-week period.&#xD;
      Participants will then undergo a calcium balance study, involving consumption of certain&#xD;
      study foods for 12 days and an overnight stay at the research unit for a calcium absorption&#xD;
      test. The calcium balance study will be followed by blood collection. At Week 5, participants&#xD;
      will be randomly assigned to receive either potassium citrate or placebo daily. For the first&#xD;
      9 weeks of treatment, there will be weekly blood collection and periodic urine collection for&#xD;
      all participants. At Month 6, blood and urine will again be collected, and participants will&#xD;
      complete questionnaires on diet and physical activity, and a second calcium balance study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>calcium balance</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 90 meq of potassium citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 60 meq of potassium citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium citrate</intervention_name>
    <description>kcitrate</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal kidney, liver, or bone function&#xD;
&#xD;
          -  Currently taking medications that might affect potassium or bone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Sellmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcium balance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

